Mass balance and metabolite profiles in humans of tegoprazan, a novel potassium-competitive acid blocker, using C-radiolabelled techniques.

Journal: Expert opinion on drug metabolism & toxicology
Published Date: May 13, 2025

Abstract

BACKGROUND: Tegoprazan (LXI-15028), a novel potassium-competitive acid blocker, has shown great efficacy in treating acid-related disorders. However, its metabolic and excretion characteristics are not fully understood.

Authors

  • Yicong Bian
    Department of Pharmacy, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
  • Jinjie Yuan
    Department of Pharmacy, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
  • Sheng Ma
    Department of Pharmacy, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
  • Jiang Nan
    Department of Radiology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
  • Zheming Gu
    Value Pharmaceutical Services Co. Ltd, Nanjing, Jiangsu, China.
  • Hao Feng
    Value Pharmaceutical Services Co. Ltd, Nanjing, Jiangsu, China.
  • Zhenwen Yu
    Value Pharmaceutical Services Co. Ltd, Nanjing, Jiangsu, China.
  • Zhenteng Liu
    Shandong Luoxin Pharmaceutical Group Stock Co. Ltd, Linyi, Shandong, China.
  • Fang Xie
    Shandong Luoxin Pharmaceutical Group Stock Co. Ltd, Linyi, Shandong, China.
  • Yinghui Wang
    Shandong Luoxin Pharmaceutical Group Stock Co. Ltd, Linyi, Shandong, China.
  • Chengxin Liu
    Shandong Luoxin Pharmaceutical Group Stock Co. Ltd, Linyi, Shandong, China.
  • Hua Zhang
    School of Clinical Medicine, Hangzhou Medical College, Hangzhou, China.
  • Liyan Miao
    Department of Pharmacy, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals